Medical Management and Device-Based Therapies in Chronic Heart Failure.

ABSTRACT: Heart failure (HF) remains a major cause of morbidity and mortality worldwide. Major advancements in optimal guideline-directed medical therapy, including novel pharmacological agents, are now available for the treatment of chronic HF including HF with reduced ejection fraction and HF with preserved ejection fraction. Despite these efforts, there are several limitations of medical therapy including but not limited to: delays in implementation and/or initiation; inability to achieve target dosing; tolerability; adherence; and recurrent and chronic costs of care. A significant proportion of patients remain symptomatic with poor HF-related outcomes including rehospitalization, progression of disease, and mortality. Driven by these unmet clinical needs, there has been a significant growth of i

SUBMITTER: Nguyen AH 

PROVIDER: S-EPMC11308856 | biostudies-literature | 2023 Nov-Dec

REPOSITORIES: biostudies-literature